Captrust Financial Advisors Bio Affinity Technologies, Inc. Transaction History
Captrust Financial Advisors
- $33 Billion
- Q3 2024
A detailed history of Captrust Financial Advisors transactions in Bio Affinity Technologies, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 27,885 shares of BIAF stock, worth $22,586. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,885
Previous 27,885
-0.0%
Holding current value
$22,586
Previous $60,000
3.33%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding BIAF
# of Institutions
15Shares Held
468KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA261KShares$211,3030.0% of portfolio
-
Geode Capital Management, LLC Boston, MA87.2KShares$70,6160.0% of portfolio
-
Sheaff Brock Investment Advisors, LLC20KShares$16,2000.0% of portfolio
-
State Street Corp Boston, MA17.6KShares$14,2560.0% of portfolio
-
Northern Trust Corp Chicago, IL13.7KShares$11,0660.0% of portfolio
About bioAffinity Technologies, Inc.
- Ticker BIAF
- Exchange
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 2,727,580
- Market Cap $2.21M
- Description
- bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is b...